Alcon, the eye care division of Novartis, saw its net sales increase to US$2.7 billion in the third quarter ended Sept. 30, up 5 percent in dollars and 6 percent in constant currencies. A positive factor was the approval given by the European Commission to Simbrinza, Alcon's new drug for ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.